PROVENTION BIO
Provention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their “predict and prevent” model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears or progresses. As such, we believe Provention is well-positioned to become a leader in a new biopharmaceutical category centered... on the interception of disease, offering the potential to reduce the high-morbidity, mortality, patient suffering and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. Provention has been carefully conceived, founded and positioned to be at the forefront of this pioneering new paradigm in medicine. They believe Provention’s business model, coupled with our expertise in translational medicine, immunology and the design and execution of rapid go/no-go clinical trials, will enable us to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.
PROVENTION BIO
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-10-04
Address:
Lebanon, New Jersey, United States
Country:
United States
Website Url:
http://www.proventionbio.com
Total Employee:
11+
Status:
Active
Contact:
212.375.2665
Email Addresses:
[email protected]
Total Funding:
423.5 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager Content Delivery Network Font Awesome Euro Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Provention Bio
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Provention Bio
Sessa Capital
Sessa Capital investment in Post-IPO Equity - Provention Bio
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series A - Provention Bio
JDRF T1D Fund
JDRF T1D Fund investment in Series A - Provention Bio
MDB Capital Group
MDB Capital Group investment in Series A - Provention Bio
Key Employee Changes
Official Site Inspections
http://www.proventionbio.com Semrush global rank: 1.67 M Semrush visits lastest month: 14.67 K
- Host name: ec2-52-210-254-87.eu-west-1.compute.amazonaws.com
- IP address: 52.210.254.87
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Provention Bio"
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
Apr 27, 2012 Sanofi completes acquisition of Provention Bio, Inc.. Paris, April 27 2023. Sanofi announced today the completion of its acquisit i on of Provention Bio, Inc.. (“Provention Bio”). …See details»
Provention Bio - Crunchbase Company Profile & Funding
Provention Bio may be growing as evidenced by the recent agreement where Sanofi has agreed to a $2.9 billion purchase of the company. This acquisition is a significant financial transaction …See details»
Press Release: Sanofi to acquire Provention Bio, adding to portfolio ...
Mar 13, 2023 Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D). Paris and Red Bank, N.J. …See details»
Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal
Mar 13, 2023 France's Sanofi SA on Monday agreed to acquire Provention Bio Inc PRVB.O for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its …See details»
Provention Bio Announces Completion of $35 Million …
Feb 13, 2023 Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio. Internet Posting of Information. Provention Bio, Inc. uses its website, www.proventionbio.com, as a means ...See details»
Changing Their World, Can Change Our World
2 Forward-looking statements. Provention Bio. This presentation contains forward‐ looking statements including, but not limited to, statements relating to the potential safety, efficacy, …See details»
Provention Bio - Pediatric Endocrine Society
About Us: Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of …See details»
Provention Bio - PitchBook
Provention Bio General Information Description. Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and …See details»
Sanofi completes acquisition of Provention Bio, Inc.
Apr 27, 2023 2/2 Nicolas Obrist | + 33 6 77 21 27 55 | [email protected] Victor Rouault | + 33 6 70 93 71 40 | [email protected] Investor Relations Eva Schaefer-Jansen | + 33 …See details»
Provention Bio - Craft
Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent …See details»
Provention Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 1, 2023 www.proventionbio.com. Public Company | Subsidiary Company | 2016 | New Jersey, United States | 100-250 | NASDAQ: PRVB | www.proventionbio.com. Last update 01 …See details»
News and Press - T1D Fund: A Breakthrough T1D Venture
LEBANON, N.J. – June 26, 2017 . Provention Bio, Inc., a recently founded clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel …See details»
Provention Bio Announces Completion of $35 Million Equity
Feb 13, 2023 Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes. RED BANK, N.J., Feb. 13, 2023 …See details»
AGC Biologics Completes PPQ Manufacturing with Provention Bio
Aug 25, 2020 Learn more at www.proventionbio.com. About AGC Biologics: AGC Biologics is a leading global Biopharmaceutical Contract Development and Manufacturing Organization …See details»
Provention Bio Announces Leadership Team Expansion - PR …
RED BANK, N.J., Dec. 20, 2021 /PRNewswire/ -- December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting …See details»
C-Path and Provention Bio Announce Data Sharing Collaboration …
For more information, please visit proventionbio.com. JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing …See details»
Provention Bio Announces Key Findings from Pre-clinical Proof
Jan 28, 2021 Partnering: Alex Rabiee, SVP, Business Development & Program Management [email protected] 908-698-4612 (EXT-118) Investor Contacts: Robert Doody, VP of …See details»
Press Release: Sanofi to acquire Provention Bio, adding to portfolio ...
Mar 13, 2023 Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) Paris and Red Bank, N.J. …See details»
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the …
Mar 13, 2023 Visit www.proventionbio.com for more information and follow on Twitter: @ProventionBio. 3/4 133476380_4 Provention Bio, Inc. is listed on Nasdaq: PRVB About T1D …See details»
Provention Bio: The Heat Is On Teplizumab For FDA Approval
Oct 26, 2022 This is my first look at Provention Bio (), another biotech that is in near term PDUFA limbo with its lead therapy teplizumab (PRV-031).In this article I review its prospects …See details»